

How to sell data to hedge funds and asset managers

Proven strategies for winning trials, clearing compliance and closing deals

Introduction and purpose	3
Buy-side data engagement lifecycle	6
Institutional data vendor lifecycle	6
Phase-by-phase playbook	7
Stage 1: Discovery & pre-call preparation	7
Stage 2: Initial call execution	11
Stage 3: Post-call materials & fund qualification	14
Stage 4: Data trial best practices	18
Stage 5: Negotiation & licensing	22
Stage 6: Decision – Go / No-go / Park	25
Next steps	26
About Neudata	

For any questions, please contact consulting@neudata.co

This whitepaper is provided for your personal use only. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means – including photocopying, recording, or other electronic or mechanical methods – without the prior written permission of the publisher, except in the case of brief quotations used in reviews or scholarly works.

Unauthorised sharing, copying, or redistribution of this material is strictly prohibited.

Introduction and purpose

The process of selling alternative data to institutional investors is notoriously opaque, slow, and high-stakes. Many data providers, despite having genuinely valuable products, fail to convert interest into engagement, or engagement into signed deals.

This playbook is designed to address that gap.

Whether you're a first-time seller or a seasoned provider entering new markets, this blueprint offers clear, actionable expectations that will reduce wasted cycles, accelerate timelines, and give you a structured path from first contact all the way to an executed licensing agreement.

Why many data providers fail to sell

While demand for data continues to rise, so do expectations. Modern investment teams operate with sophisticated analytics models, compliance, engineering, and legal frameworks. They are inundated with vendor outreach, yet only a small fraction of data products ever make it to trial, let alone procurement.

This is not because the rest are irrelevant.

It's because most vendors:

- Fail to articulate their data's investment relevance
- Show up to calls without the right materials
- Are caught off guard by compliance discussions or contract edits
- Struggle with trial delivery or over-curation
- Misunderstand how their data fits into the buying organisation's processes

Winning providers succeed not just because of what their data contains, but because of how they align their process and business model to investor expectations.

How to succeed

This playbook provides the knowledge you need to succeed at each step of the **data adoption lifecycle**.

1. **Discovery** – How to be taken seriously (or instantly disqualified)
 2. **Intro call** – What funds test for in the first 30 seconds
 3. **Post-call qualification** – The document bundle that gets you trial access
 4. **Data trial** – How to make your data usable, testable, and trusted
 5. **Negotiation** – The legal landmines and pricing moves that make or break deals
 6. **Decision** – Why funds say “yes,” “no,” or silently walk away
- The fastest-growing vendors do three things exceptionally well:
 - Tell a one-sentence investment story (“This dataset helps long/short PMs anticipate restocks 4 weeks ahead of earnings”).
 - Send a perfect post-call package within 48 hours (schema, DDQ, tear sheet, legal clarity, point-in-time sample).
 - Treat the trial like a client onboarding, not a data dump.
 - Legal and compliance are not roadblocks; they are the decision-makers.
 - Vendors who can’t confirm the dataset’s compliance profile, or explain how the data was sourced will have difficulties or be disqualified.

Guiding philosophy

Alpha is not enough.

The most successful data providers don’t just prove their data has signal, they make it easy for funds to trust it, test it and license that signal.

This guide is designed to make that possible for any provider, regardless of experience, size, or industry.

Buy-side data engagement lifecycle


Institutional investors, particularly hedge funds and asset managers, tend to follow a repeatable but opaque internal process when evaluating new data vendors. While each firm has its own variation, the overall lifecycle is generally consistent across the industry.

This section outlines the lifecycle from the data buyer's perspective, so providers can:

- Understand the needs of the buyer and what is happening behind the scenes
- Anticipate the next step in the process and avoid raising red flags
- Deliver the right materials and responses at the right time
- Identify where their deals are stalling, and why

The stages below have been mapped and validated against real processes from multiple funds.

Institutional data vendor lifecycle



The fund's compliance, engineering, research, and legal teams will progressively get involved at different stages. The vendor's ability to stay aligned with expectations in each phase directly influences whether the process advances or collapses. *These steps can and should become the outline for managing your sales funnel.*

Phase-by-phase playbook

Stage 1: Discovery & pre-call preparation

Stage objective:

Determine whether the data provider is credible, relevant, and worth spending time on.

What buyers are doing:

Buyers aren't sitting idle waiting for vendors to show up. They're actively scanning the market for credible signals of value – whether through peer referrals, research platforms, or events. Before a conversation even happens, they've often formed an early impression based on reputation, perceived risk, and potential fit. If your data doesn't clear these first few filters, you may never know you were being evaluated in the first place.

Buy-side goal

At this early stage, institutional investors are quickly screening vendors — often based on a cold email, a conference interaction, or a platform profile. Their goal isn't to fully understand the dataset yet; it's to answer three foundational questions:

1. Does this data solve a real investment problem?
2. Can we trust the vendor's credibility and sourcing?
3. Is it worth assigning internal resources to explore further?

Even when a buyer shows initial interest, some won't agree to a call – unless the vendor can clear the filters.

This is why strong first impressions matter: if your positioning doesn't immediately address these questions, the conversation may die very quickly or may never start.

What funds want to see (before the call)



Scanning for credible signals of value (through platforms, events, referrals, research)



Vetting reputation, founder background, legal red flags



Asking: 'Do I believe there is something we need or want in this data?'

Is this data worth pursuing?

Does this data solve a real investment problem?

Can we trust this vendor's credibility, source and legality?

Is this worth assigning an analyst or engineer's time?

This is the pre-call filter. Most buy-side firms have developed an informal checklist similar to the one below. If vendors don't check enough boxes, no call is scheduled:

- ☐ **One-line value proposition** - A clear statement of what the data tracks, predicts, or enables
- ☐ **Use case framing** - 1-2 examples of how a fund could actually use this data to inform positions or signals
- ☐ **Data snapshot** - A few rows of sample data (real, not dummy), showing field names and structure
- ☐ **Basic schema** - Field names, data types, update frequency, start date, delivery format
- ☐ **Coverage summary** - Assets/sectors tracked, region, history depth, refresh cadence
- ☐ **Origin story** - Clear explanation of where data comes from and how it is collected (first-party, scraped, licensed, etc.)
- ☐ **Legitimacy markers** - Founders, backers, existing clients, or affiliations
- ☐ **Tear sheet or one-pager (optional)** - If clean and non-generic, this helps consolidate key details into a single artifact

Additional insight:

Modern SDR best practices

Outreach must be tailored by strategy: quant funds need latency, history, and coverage specifics, while fundamental funds want stories, visuals, and alpha pathways. Most importantly, buyers don't want "data", they want insight. Frame your outreach around macro patterns or sector dislocations (e.g., retail traffic collapses or hiring reversals) rather than company-specific anomalies.

Common mistakes vendors make at this stage

Mistake	Why It fails
Statements like “we track macro sentiment via AI”	Too vague. No investable anchor
No sample schema or dictionary	Funds can’t estimate internal engineering cost
Weak or generic marketing materials	If your materials don’t say how the data can be used, they hurt more than help
Unclear or hidden sourcing	Funds avoid MNPI or GDPR issues
No articulation of who uses this	“Who is this for?” is a filtering question. If you don’t know, they won’t guess

What great vendors do

Tactic	Outcome
Lead with one sentence that includes the asset class or economic signal	Instantly clear alignment
Share a 5-row real data sample inline in your intro email or listing	Signals transparency + professionalism
Offer a structured one-pager: use cases, schema, sectors, delivery, history	Helps the buyer circulate internally
Acknowledge any limitations (e.g. “data is sparse before 2020”)	Earns trust early
Mention delivery readiness (e.g. format is CSV; delivery via S3, Snowflake, sFTP etc)	Shows fit into industry-standard pipelines

Internal litmus test: "Are we ready for a call?"

Before requesting a fund meeting, ask:

- ☐ Can we explain in one sentence what our data lets a portfolio manager do?
- ☐ Do we have a clean schema and sample ready to send?
- ☐ Are we willing to disclose source type (first-party, scraped, etc.)?
- ☐ Do we have a use case that names a sector or trading style?
- ☐ Can we answer the question: "What would I see if I opened the CSV?"

If not, pause and prep. Institutional investors don't give second chances at the pre-call stage.

Output expectation for this phase

At the end of the discovery phase, a buyer should be able to say:

- ☐ "This vendor appears credible."
- ☐ "I understand what this data does."
- ☐ "This could plausibly inform one of our strategies."
- ☐ "It's worth booking a call to learn more."

Fail to hit those four boxes, and the process ends here.

Additional Insight**Modern SDR best practices**

Modern institutional buyer-facing teams are evolving. SDRs are no longer just appointment setters, they must be technically literate, full-stack operators who understand hedge fund mental models. Handing off a lead after one email or call is now seen as friction. In top-performing teams, SDRs and AEs jointly own top-of-funnel, scoring leads using tools like Gemini, Perplexity, or dashboard overlays of 13F filings, sector exposures, and turnover. KPIs now emphasise qualified meetings over raw volume to reduce buyer fatigue.



How Neudata can help

Neudata helps you perfect the first impression. We help you distil your dataset into a one-liner that buyers can easily repeat to colleagues, illustrate it with two practical use cases, and prepare a clear tear sheet and sample rows. We also review your DDQ and create a selling FAQ so you can confidently handle compliance questions. Finally, we identify which funds and other buyers are most likely to be interested in your data so you can focus your efforts where they matter.

Result: You'll approach buyers as credible, relevant and ready for trial consideration.

Stage 2: Initial call execution

Stage objective:

Test the vendor's relevance, technical depth, and commercial readiness, live.

What buyers are doing:

- Mapping the dataset to an internal investment persona or personas
- Testing whether the vendor understands their own data
- Evaluating the tone, clarity, and transparency of the provider

Buy-side goal

The introductory call is where the data buyer determines:

- "Is this vendor legitimate and aligned with our needs?"
- "Do they understand their data and how it could help us trade?"
- "Is this worth pushing through compliance and engineering review?"



Even if a call is granted, the buyer is likely multitasking, sceptical, and managing dozens of vendors in parallel. The bar is high. The expectation is clarity, not charm.

What funds expect on the first call

Buyers use the call to assess signal strength, operational readiness, and legal risk. Expect questions like:

Buyer question	What they're really testing
"Where does your data come from?"	Can you legally sell this?
"What sectors/assets does it help us trade?"	Do you understand how we think?
"How often is it updated?"	Can it support our signal refresh rate?
"Do you have backtests or use cases?"	Have others found this valuable, or is this theory?
"Is the data first-party or scraped?"	Are we going to run into GDPR/MNPI issues?
"How is the data delivered?"	Will this break our pipeline or take engineering time?
"How far back does the history go?"	Can we test this against historical trades?

What you must communicate on the call

Topic	Description
Core value	What the data tracks, and what it lets an investor do (e.g. predict restocks, measure job transitions, infer volume)
Use case	Two real-world scenarios: "A long/short equity PM could use this to..."
Source legality	Explain sourcing clearly: is it collected, licensed, scraped? Can you legally sell it?
Delivery format	Specify: S3, Snowflake, sFTP. Bonus: GUI or API access options
Schema & coverage	Number of rows, columns, assets, sectors, regions, and frequency
Known limitations	Own your weaknesses (e.g. "Gaps in Q2 2021 due to upstream feed loss")
Trial willingness	Confirm you can offer a free, time-bound trial with standard docs

Common call-killer mistakes

Mistake	Why it fails
Overhyping alpha	"We beat the market" raises red flags
No idea how data is used	If you can't explain use cases, the fund won't know them
Vagueness about sourcing	Triggers legal paranoia, especially around scraping
Defensive attitude	If you resist questions, you lose trust. Be honest about data weaknesses (sparsity, partial history, etc.)
The salesperson talks too much	Buyers want depth, not surface-level pitch

Advanced best practices

Tactic	Impact
Be able to name 1–2 competitor datasets	Gives an opportunity to show how your data is differentiated
Walk through a CSV live (screenshare)	Shows you're transparent and confident
Reference other buy-side use (without naming clients)	Signals traction and relevance
Proactively ask: "What matters most to your team right now?"	Builds trust, customises follow-up
Offer to send trial + DDQ immediately after	Reduces cycle lag, shows you're buttoned-up

Internal buyer rubric

Buyers often leave the call asking:

- "Did I understand what this dataset does?"
- "Can I explain it to my PM or compliance team in one sentence?"
- "Are they confident, not cagey?"
- "Are they ready for next steps (trial + docs)?"

If the answer to most of these is "no," the process stalls, often silently.

Mental model for the call

The real sale starts after the trial. The first call is simply about passing the gate.



You are not trying to sell the data.
You are trying to earn the right to be tested.

Output expectation for this phase

By the end of this call, the buyer should:

- Understand the data's origin, schema, and potential value
- Have a sense of how it could map to their investment process
- Feel confident that the trial, legal, and compliance next steps can be handled efficiently
- Be willing to request a trial or advance to material review

Top vendors aggressively pre-qualify before issuing trials. Extracting 1-3 use cases upfront forces buyers to articulate hypotheses, increasing trial success. Avoid “free trials as bait.” Instead, make the buyer earn it by showing clear engagement and internal buy-in. Trials that convert rarely happen by accident. They typically follow a structured but flexible setup, lightweight agreements, frictionless access, and the right stakeholders at the table. The best trials aren’t just technical – they’re multi-threaded across investment, engineering, and compliance. Miss one, and the whole thing can quietly stall out.

There is no perfect model for approaching trials; every data provider has different attributes and every buyer has slightly different needs. We’ve seen many different models succeed, depending on the dataset and buyer, but common patterns do emerge. Knowing what matters most in each situation can save weeks of effort (or prevent a quiet “no”). **Both parties should know and agree upon the criteria for measuring the success of a trial.**



How Neudata can help

Neudata scripts your first call so you can cover value, use cases, compliance, and delivery in under 15 minutes. We coach you to present with confidence, acknowledge limitations openly, and walk through your data clearly. You'll also leave with concise answers on sourcing, rights and differentiation, plus a close that earns the rights to a trial without coming across as pushy.

Result: Buyers finish the call saying "I get it, I trust it, and I want to test it."

Stage 3: Post-call materials & fund qualification

Stage objective:

Deliver documentation and data samples that enable legal, compliance, engineering, and research teams to evaluate the vendor for trial readiness.

What buyers are doing:

- Requesting schema, DDQ, tear sheet, sample data
- Running internal compliance checks (e.g. PII, MNPI, GDPR)
- Asking legal to review NDA and potential license templates

Buy-side goal

Once a vendor clears the first-call bar, the buyer's mindset shifts from curiosity to risk management and technical due diligence. At this stage, the fund is asking:

- "Can we test this without triggering legal/compliance alerts?"
- "Can we integrate this without pain?"
- "Do we trust this vendor's documentation and transparency?"



Most deals fail here, not because the data is bad, but because vendors can't provide clean materials fast enough or fail to meet internal standards for documentation, data quality, or legal clarity.

What funds expect post-call (within 24–72 hours)

Asset	Description
Data dictionary	Clean description of each column, format, units, null behaviour, and any derived/calculated fields
Schema file	Table format: Field Name
Sample dataset	3–6 months of real, structured, point-in-time data (not dummy data). Must reflect post-sale delivery quality
Coverage overview	Geographic, sector, ticker, or entity coverage + historical depth
Tear sheet or slide summary	1–2 page artefact that includes: use cases, sourcing method, update frequency, delivery method, pricing tier (optional), trial terms
Completed DDQ	Based on FISD or similar formats; partial is okay if well organised
Legal clarity statement	Confirm that data contains no MNPI, PII, or GDPR violations; state data sourcing rights clearly
Trial terms	Proposed scope, timeline, delivery method, and free trial terms (expected)
Trial agreement template	Three pages max, includes NDA, trial scope, 30–60 day limit, and no commercial usage clause. Some funds may require you to use theirs
Extended history sample	Ideally, buyers want 5+ years of point-in-time data to enable proper backtesting. Shorter histories may reduce conversion likelihood
Ticker mapping compatibility	The dataset should be compatible with common symbology (e.g. tickers, LEIs, company names). Without it, many funds won't test the data
Structured delivery format	Funds expect delivery via S3, sFTP, or Snowflake, not email or shared drives. Data should be logically partitioned (e.g. by date, entity, sector)

Clarity on data rights

A simple, clear statement confirming that the provider has rights to collect, distribute, and license the data legally, without exposure to MNPI, PII, or GDPR violations

Some buyers also require a minimum threshold of historical depth, typically 5 years, for meaningful testing. Others will disqualify vendors whose samples are incomplete, not point-in-time structured, or not symbology-mapped to tradable assets. Structurally, vendors should avoid sending enormous, unpartitioned CSVs or fragmented sample packs. Clean delivery (e.g. foldered by month or year) helps engineers evaluate feasibility faster.

Optional but valuable

Asset	Why It helps
GUI Preview or data browser	Reduces ingestion friction for research teams
Example Jupyter Notebook or dashboard	Shows immediate usability
Coverage/History heatmap	Clarifies sparsity, refresh rates, and ticker/entity density
Sample use case slides	Helps buyers socialise internally with PMs or data leads
Pricing ranges	Optional, but can help set commercial expectations early

What kills momentum at this stage

Mistake	Consequence
Delayed follow-up (>5 days)	Fund deprioritises the vendor and never follows up
Poorly formatted data dictionary or schema	Signals a lack of technical maturity
Dummy or incomplete sample dataset	Fails compliance check, destroys trust
No clarity on data sourcing rights	Legal blocks the trial
Hidden MNPI or PII concerns	Causes an immediate red flag or legal shutdown

Internal buyer workflow (What happens after you send materials)

1. Data engineering reviews the structure and ingestion feasibility
2. Compliance reviews source, rights, and risk (MNPI, GDPR, PII)
3. Legal may request standard NDA, MDSA, or vendor onboarding forms
4. Research evaluates whether to pursue a trial (and under what hypothesis)
5. Commercial begins thinking about pricing benchmarks and licensing structure



This is not a passive phase. Silence from the fund = bad sign. If you haven't heard back in 5-7 days, follow up.

Vendor checklist: Fund qualification readiness

Before sending materials, confirm:

- ☐ Is my schema professionally formatted and labelled?
- ☐ Can the sample dataset be ingested immediately by the fund's engineering team?
- ☐ Have I explicitly stated where this data comes from and why it's legal to sell?
- ☐ Did I include both a CSV and a visual summary (e.g. slide deck, tear sheet)?
- ☐ Is there anything in the sample that could trigger PII/MNPI questions?

Output expectation for this phase

By the end of the post-call material review, the fund should:

- Have full technical and legal confidence to proceed
- Be able to route the vendor to appropriate internal teams (trial, legal, compliance)
- Be ready to schedule a second call or trial kickoff
- Or, if misaligned, respectfully decline or park the conversation

Vendors must ring-fence trial timelines. Trials that leak past 60 days often drift and die. Set firm checkpoints: kickoff, midpoint check-in (e.g. day 30), and trial close.



How Neudata can help

Neudata ensures you can deliver a complete post-call package within 48 hours: schema, data dictionary, 3–6 months of sample data, coverage and history overview, DDQ, and a short, buyer-friendly trial agreement. We help you package these clearly so legal and engineering teams get what they need without delay.

Result: Momentum continues, and you stay at the front of the buyer's pipeline.

Stage 4: Data trial best practices

Stage objective:

Allow the buyer to fully evaluate the dataset under real conditions, technically, legally, and strategically, before committing to a license.

What buyers are doing:

- Ingesting the dataset into internal pipelines (S3, Snowflake, sFTP)
- Testing signals against live or historical models
- Validating delivery quality and engineering hygiene
- Evaluating service responsiveness

Buy-side goal

At this stage, the fund has decided:

"This vendor is worth testing. Now let's see if their data actually works."



The trial phase is the most critical turning point in the entire engagement lifecycle. It's where promising conversations turn into proof, or collapse under the weight of integration failure, legal missteps, or unmet expectations.

Buyers use this phase to answer:

- Can we ingest this without breaking things?
- Can it generate alpha or decision-making edge?
- Is the vendor technically competent and responsive?
- Will this scale across our investment team?

Trial setup: What buyers expect

Element	Expectation
Free trial access	Industry standard; paid trials are almost always rejected
Trial agreement (MDSA)	Mutual NDA + brief MDSA outlining trial terms
Defined timeline	Typically 30–60 days with optional extension
Data delivery method	S3 or Snowflake preferred; sFTP is acceptable; no email/Google Drive
Point-in-time sample	Must reflect how data will be delivered in production
Ticker mapping / Entity matching	Ideally included or compatible with fund symbology
Column-level documentation	Match field names to descriptions for smooth ingestion
Trial support contact	One dedicated person from the vendor for fast troubleshooting
Partitioned file structure	Datasets should be chunked by time (e.g. Y/M/D) or region. Monolithic or disorganised files often stall ingestion and derail trials

Great vendors treat the trial setup like onboarding a client, not just dumping a CSV.

What funds are testing during the trial

Dimension	What they're looking for
Technical hygiene	Can they ingest the dataset with minimal support?
Data stability	Are fields, formats, and refreshes consistent?
Schema completeness	Are there unexplained nulls or gaps?
Backtestability	Does the history line up with trade hypotheses?
Signal validity	Does it correlate with anything economically meaningful?
Support response time	Does the vendor respond to issues in <24 hrs?
Transparency	Can the vendor explain derivation, aggregation, or enrichment logic clearly?

Trial-killing mistakes to avoid

Mistake	Consequence
Over-orchestration (over-cleaning or cherry-picking)	Misrepresents real-world performance, destroys trust
Lack of version control or field consistency	Makes trial data unusable
Unexplained column names or codes	Causes ingestion delays and frustration
No scheduled check-ins during trial	Leads to passive disengagement
FTP or email-based delivery	Triggers internal risk flags or blocks automation
Missing ticker/entity symbology	Adds engineering workload; often kills momentum
Failure to disclose biases or gaps in history	Undermines trust; buyer assumes you're hiding structural flaws

Best practices for a high-conversion trial

Action	Why it works
Offer multiple delivery formats (CSV, Parquet, Snowflake)	Meets each fund's stack preferences
Provide a simple README or onboarding doc	Speeds up time-to-evaluation
Schedule mid-trial check-in calls	Keeps fund teams engaged and aligned
Include Jupyter notebook, dashboard, or Excel demo	Helps show "how to use" in real terms
Let the buyer keep the trial data post-trial	Makes re-engagement easier months later
Track coverage requests or edge cases	Allows you to iterate during trial to meet evolving needs

Optional enhancements

Enhancement	Impact
GUI/Data portal	Helps non-engineers explore the dataset
Tagging system (e.g. sector, theme, geography)	Improves usability for PMs
Pre-loaded use case examples	Shortens the time to alpha validation
Pre-built ticker-mapped version	Reduces onboarding friction dramatically

Trial design template

Item	Example
Trial period	30-60 days
Start date	e.g. 1st July 2025
Dataset scope	Full dataset, last 2 years, all fields
Delivery	Snowflake + S3 fallback

Evaluation goals	Correlation with company revenue, restocking patterns
Check-ins	Week 1, week 3, final week
Success metric	Alpha signal, ingestion ease, coverage match

Output expectation for this phase

By the end of the trial, the buyer should:

- Have successfully ingested and explored the dataset
- Have an internal opinion on signal strength or operational value
- Be ready to advance to licensing discussion, or decide not to move forward
- Feel that the vendor was responsive, transparent, and technically sound



How Neudata can help

Neudata helps you treat the trial as guided onboarding. We set clear success criteria, ensure delivery “just works” and help prepare plain-English schema docs so research teams can test quickly. We also establish week-1, midpoint, and closing check-ins, and help you respond to buyer queries within 24 hours.

Result: Time-to-first-query drops, stakeholders stay engaged, and you finish the trial with advocates inside the fund.

Stage 5: Negotiation & licensing

Stage objective:

Align on commercial terms, legal agreements, and usage rights to move from trial to live production.

What buyers are doing:

- Reviewing pricing structures
- Requesting edits to contracts (e.g. reps and warranties, liability)
- Checking procurement policy boxes (vendor onboarding forms, SLAs)
- Comparing to other vendors or internal alternatives

Buy-side goal

At this stage, the trial has demonstrated signal or operational value. The buyer is now asking:

- “Can we legally license this without creating risk?”
- “Is the vendor flexible enough to work within our policies?”
- “Is the pricing structure aligned with our budget and use case?”



This is not a rubber-stamp phase. It is a multi-party, zero-risk tolerance process, involving compliance, legal, procurement, engineering, and often a pricing committee.

What funds expect at this stage

Element	Expectation
Final license agreement (DELEA or similar)	Should reflect fund-standard language and allow for negotiation
Pricing transparency	Line-item pricing (base, tiers, add-ons); history must be included
Historical data included	Bundled into the first-year price; charging extra is a common deal killer
Trial terms reflected	Trial onboarding period (30–60 days) must be free and excluded from the license term
Volume/scope flexibility	Ability to slice by ticker, region, or sector
Warranties and indemnities	Confirmation of legal right to sell, no MNPI, no breach of GDPR or CCPA
Data refresh cadence	Must be clearly defined and enforced via SLA
Audit clauses	Funds may require audit rights for compliance monitoring
Renewal structure	Prefer annual or short-term, with modest price increases (<5%)

Pricing preferences

Term	Expectation
Trial period	Free; onboarding time not billed
Multi-year commitments	Avoided unless there is a significant discount (>20%)
Historical data access	Included in base license
Year-over-year pricing increases	Capped at 5% (without added coverage/features)
Slice-based packaging	Buyer should be able to license by subset (e.g. US equities only)
Freemium add-ons	Visualisation portal, API, and ticker mapping should be bundled for the first year, where possible
Payment terms & termination rights	Payment and termination provisions should align with standard commercial practice. Buyers frequently push back when providers demand full annual prepayment or reserve one-sided termination rights. The market norm is monthly invoicing on annual contracts, with quarterly billing occasionally acceptable.

Deal-killing legal & contractual mistakes

Mistake	Consequence
Adding irrelevant or overly restrictive terms on use of data with AI/ML tools	Creates friction and confusion; slows negotiations. Only acceptable limits are: (i) use must remain on client-controlled networks, (ii) no redistribution of models/results/derivatives, and (iii) no pre-training rights.
Refusing edits to PII/MNPI clauses	Inability to revise or clarify leads to 2–4 week legal stalls
Charging separately for historical data	Viewed as 'nickel-and-diming'; causes pricing friction or walkaway
Vague language around sourcing rights	Compliance rejects the contract
Excessively aggressive IP protection language	Slows negotiation or creates red flags
Not providing warranties/indemnities	Non-starter for institutional buyers

Long-term auto-renewals with no opt-out	Seen as predatory; often killed at procurement level
Refusing to confirm upstream data rights	Seen as a risk of illegal distribution; legal and compliance block the contract
No clarity on data origin or sourcing rights	Compliance assumes worst-case scenario

Best practices for a smooth licensing process

Action	Why it works
Send a redline-friendly Word version of the agreement	Legal teams can edit easily
Pre-state willingness to negotiate key clauses	Reduces post-trial delays
Offer a 'starter package' with upgrade paths	Makes budget conversations easier
Align billing with deployment date (not trial start)	Improves buyer perception of fairness
Assign a single point of contact for legal and commercial	Reduces email fragmentation
Provide a renewal notice clause	Prevents friction at year-end or re-evaluation time

Internal buyer dynamics (What's happening behind the scenes)

- Legal and compliance are negotiating risk
- Procurement is reviewing onboarding docs, tax forms, billing structure
- Investment or data leads are advocating for usage
- Budget owners are reviewing commercial fairness vs alternatives
- Stakeholder trust is being weighed based on vendor behaviour

If your approach is rigid, opaque, or slow during this phase, you will lose the deal even if the trial went well.

Output expectation for this phase

By the end of the negotiation phase, the fund should:

- Have a clean, signed agreement with clear usage, delivery, and pricing terms

- Feel that legal, compliance, and engineering risks have been addressed
- Be ready to move the vendor into live onboarding, billing, and production use



How Neudata can help

Neudata helps de-risk the contracting stage. We provide market-tested templates and best practices for your legal team, along with pricing benchmarks and playbooks so you hold margin without stalling the deal. We also guide procurement tasks - onboarding forms, SLAs, billing - so the process moves smoothly from trial to live license.

Result: faster signatures, fair terms, and a commercial structure that supports renewal and growth.

Stage 6: Decision – Go / No-go / Park

Goal: Final internal alignment on value vs risk.

Buyer options:

- Go: License begins, data enters production
- No-go: Deal killed (usually due to legal, pricing, or data quality)
- Park: Not relevant now, but may revisit in 3-12 months

Vendor response strategy:

- If “No,” request a brief exit call or written RCA (Root Cause Analysis)
- If “Park,” ask for permission to check back on a specific date
- Track decision-maker preferences to reframe later

Sophisticated vendors treat “No” as a long-term learning input, not a failure.



How Neudata can help

Neudata supports you, whatever the outcome. We refine your product story, ICP and USPs, and if the deal pauses, we help you reframe for a smarter second attempt or direct you toward better-fit prospects in our network. We also connect you with buyers through our platform and Data Summits, where providers and funds build long-term relationships.

Result: Every decision point becomes a step forward - toward a live deal, a stronger next pitch, or a new buyer.

Next steps

Selling data into the investment industry is challenging, but you don't have to do it alone. This guide was produced by the Neudata Consulting team, drawing on firsthand experience supporting hundreds of data evaluations, trials, and commercial negotiations between data vendors and institutional investors.

Neudata partners with providers at every stage of the sales journey — from shaping your pitch to securing trials and navigating compliance. If you'd like expert guidance on your next step, email consulting@neudata.co to arrange an initial consultation.

About Neudata

Neudata was founded in 2016 with a clear mission: to help investors and data providers succeed in the alternative data ecosystem. Today, we are a team of 80+ experts, with offices in London, New York and Shanghai, combining data scouting, consulting, technology, and events to support both sides of the market.

We work with 1,000+ alternative and traditional data vendors, helping them understand investor needs, refine their products, and position their datasets for fund adoption. Our consulting team specialises in data

monetisation: shaping raw datasets into fund-ready products, developing go-to-market strategies, and guiding providers through trials, compliance, and licensing.

On the buy side, more than 1,000 institutional investors use Neudata's Scout platform to evaluate data. Together, these clients represent 60–70% of industry-wide spending on alternative data.

Unlike brokers, we never take commissions or resell your data. Providers transact directly with buyers. Our role is to accelerate your path to revenue by giving you insight into what funds want, helping you avoid common pitfalls, and connecting you with real opportunities to monetise your data.

Contact consulting@neudata.co and ask for an initial consultation.